Adolor said that the compound was previously studied by a pharmaceutical company in late-stage clinical trials in over 1,000 patients for the treatment of depression, where it demonstrated a good safety profile.
Adolor is repositioning ADL6906 as a potential treatment for pain conditions and currently is conducting Phase 1 clinical evaluation of the compound.
The ongoing Phase 1 multiple ascending dose study is evaluating the safety, tolerability and pharmacokinetics (PK) of ADL6906 administered orally twice daily over 10 days in healthy volunteers.
Adolor president and CEO Michael Dougherty said that they are pleased to announce the issuance of this patent for ADL6906.
"ADL6906 represents an important addition to our clinical development portfolio, and we look forward to reporting on our progress in further studies," Dougherty said.